Monitoring Anticoagulation with Unfractionated Heparin on Renal Replacement Therapy. Which Is the Best aPTT Sampling Site?
References
- Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005;294:813-8.
- Violo L, De Francesco M. Timing of Continuous Renal Replacement Therapy. JAMA Surg. 2018;153:289-90.
- Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:179-84.
- Fealy N, Aitken L, Toit Ed, Baldwin I Continuous renal replacement therapy: current practice in Australian and New Zealand intensive care units.Crit Care Resusc. 2015; 17:83-91.
- Gould D, Doidge J, Sadique M et al. Renal replacement anticoagulant management: Protocol and analysis plan for an observational comparative effectiveness study of linked data sources. Journal of the Intensive Care Society 2020 <a href="https://doi.org/10.1177/1751143720913417" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1177/1751143720913417</a>
- Brandenburger T, et al. Renal replacement therapy and anticoagulation. Best Practice $ Research Clinical Anesthesiology 2017;387-401
- Clark W, Villa G, Ronco C. Continuous Renal Replacement Therapy Machine Technology, Critical Care Nephrology, 2019,141;853-860
- Meersch M, Küllmar M, Wempe C, et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial. BMJ Open. 2019;9(1)
- Oudemans-van Straaten HM, Kellum JA, Bellomo R. Clinical review: anticoagulation for continuous renal replacement therapy--heparin or citrate? Crit Care. 2011;15:202.
- Miklaszewska M, Korohoda P, Zachwieja K, et al. Filter Size Not the Anticoagulation Method is the Decisive Factor in Continuous Renal Replacement Therapy Circuit Survival. Kidney Blood Press Res. 2017;42:327-37.
- Martindale SJ, Shayevitz JR, D’Errico C. The activated coagulation time: suitability for monitoring heparin effect and neutralisation during pediatric cardiac surgery. J Cardiothorac Vasc Anesth. 1996;10:458-63.
- Aarab R, van Es J, de Pont AC, Vroom MB, Middeldorp S. Monitoring of unfractionated heparin in critically ill patients. Neth J Med. 2013;71:466-71.
- Li F., Gross A. Considerations for Medication Management and Anticoagulation During Continuous Renal Replacement Therapy. AACN Advanced Critical Care, 2017,28(1), 51–63
- Ostermann M, Dickie H, Tovey L, Treacher D. Heparin algorithm for anticoagulation during continuous renal replacement therapy. Crit Care. 2010; 14:419
- Gabrielli A, Layon AJ, Yu M, Civetta JM, Taylor RW, Kirby RR. Civetta Taylor and Kirbys Critical Care, Fourth Edition. Philadelphia: Lippincott Williams & Wilkins, 2009. Print.
- Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 Suppl):64S–94S
- de Swart CA, Nijmeyer B, Roelofs JM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood. 1982;60:1251-8
- Coene KLM, van der Graaf F, van de Kerkhof D. Protocolled Redefinition of the Therapeutic Range for Unfractionated Heparin: Lost in Translation?. Clin Appl Thromb Hemost. 2018;24:164-71
- Shapiro GA, Huntzinger SW, Wilson JE 3rd. Variation among commercial activated partial thromboplastin time reagents in response to heparin. Am J Clin Pathol. 1977;67:477-80.
- Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost. 2006;96:547-52.
- Niederdöckl J, Dempfle CE, Schönherr HR, et al. Point-of-care PT and aPTT in patients with suspected deficiencies of coagulation factors. Int J Lab Hematol. 2016;38:42-34.
- Stein P, Kaserer A, Spahn GH, Spahn DR. Point-of-Care Coagulation Monitoring in Trauma Patients. Semin Thromb Hemost. 2017;43:367-74.
- Zimmerman CR. The role of point-of-care anticoagulation monitoring in arterial and venous thromboembolic disorders. J Thromb Thrombolysis. 2000;9:187-98.
- Baldwin I, Bridge N, Heland M, et al. The effect of heparin administration site on extracorporeal circuit life during continuous venovenous hemofiltration. Aust Crit Care 1996;1:29.
- Leslie GD, Jacobs IG, Clarke GM. Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration. Intensive Care Med. 1996;22:1261-4.
- Brain M, Winson E, Roodenburg O, McNeil J. Non anticoagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrol. 2017;18:69.
- Laxson CJ, Titler MG. Drawing coagulation studies from arterial lines: an integrative literature review. Am J Crit Care. 1994;3:16-24.
- Kordzadeh A, Austin T, Panayiotopoulos Y. Efficacy of normal saline in the maintenance of the arterial lines in comparison to heparin flush: a comprehensive review of the literature. J Vasc Access. 2014;15:123-7.
- Moossavi S, Vachharajani TJ, Jordan J, Russell GB, Kaufman T, Moossavi S. Retrospective analysis of catheter recirculation in prevalent dialysis patients. Semin Dial. 2008;21:289-92.
Language: English
Page range: 159 - 166
Submitted on: Feb 25, 2020
Accepted on: Jun 26, 2020
Published on: Aug 11, 2020
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2020 Florin Ioan Anton, Paul Adrian Rus, Natalia Hagau, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.